What question did this study set out to answer?

This trial aims to reduce treatment toxicity and improve survival rates in pediatric patients with acute lymphoblastic leukemia through risk stratification.

February 20, 2008BloodOpen Access

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

View Full Paper

Ask AI

Bookmark

Authors

AMAnja MörickeUniversity Medical Center ARAlfred ReiterJustus-Liebig-Universität Gießen MZMartin ZimmermannMedizinische Hochschule Hannover

Discussion

Member takes

Implication

Randomized trial evaluates risk-adjusted treatment outcomes in pediatric acute lymphoblastic leukemia, suggesting better survival and reduced treatment burdens.

Key Points

This trial aims to reduce treatment toxicity and improve survival rates in pediatric patients with acute lymphoblastic leukemia through risk stratification.
Trial enrolled 2169 pediatric and adolescent patients with acute lymphoblastic leukemia.
Patients were categorized into risk groups based on factors like age, white blood cell count, and genetic aberrations.
Interventions included treatment intensification for high-risk groups and reduced treatment for standard-risk patients.
Overall 6-year event-free survival was 79.6% (+/- 0.9%).
Standard-risk patients had a 6y-EFS of 89.5% (+/- 1.1%) with reduced anthracyclines.
High-risk patients showed a 6y-EFS of 49.2% (+/- 3.2%) following intensified treatment.

Cite This Study

Möricke et al. (2008) studied this question.

synapsesocial.com/papers/6a10ee3239dd87f6d0ee95ab https://doi.org/10.1182/blood-2007-09-112920

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates risk-adjusted treatment outcomes in pediatric acute lymphoblastic leukemia, suggesting better survival and reduced treatment burdens.

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Discussion

Member takes

Implication

Key Points

Cite This Study

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider